Biosimilars Education Impact Assessment Questionnaire

Before Training

What do you know about biosimilars?

Q1a. Before this training, had you heard the term “biosimilar/biosimilarity” in the last month?  
No  Yes

Q1b. How well do you understand how biosimilar medicines are developed?

I know nothing  I have extremely good knowledge

0 1 2 3 4 5 6 7 8 9 10

Q1c. How well do you understand how biosimilars are licensed in the UK?

I know nothing  I have extremely good knowledge

0 1 2 3 4 5 6 7 8 9 10

Q1d. How well do you understand the concept of extrapolation in regards to biosimilars?

I know nothing  I have extremely good knowledge

0 1 2 3 4 5 6 7 8 9 10

Biosimilars in your practice:

Q2a. How would you expect patients to respond clinically to biosimilars compared to the reference/original medicine?

Very much differently  Somewhat differently  Somewhat the same  Very much the same  Not Sure

Q2b. How confident would you be in using biosimilars in your patients?

Not at all confident  Very confident

0 1 2 3 4 5 6 7 8 9 10

Q2c. How easy do you think it will be to introduce biosimilars into your department?

Impossible  Straightforward

0 1 2 3 4 5 6 7 8 9 10

Q2d. What issues do you expect to arise if biosimilars are introduced into your department?

--------------------------------------------------------------------------------------------------------
Talking about biosimilars:
Have you ever had a discussion about biosimilars with:

Q3a. Clinical colleagues: No Yes

How confident were you at explaining what a biosimilar is:
Not at all confident
0 1 2 3 4 5 6 7 8 9 10
Very confident

Q3b. Patients: No Yes

How confident were you at explaining what a biosimilar is:
Not at all confident
0 1 2 3 4 5 6 7 8 9 10
Very confident

Biosimilar training

Q4a. Have you previously received any training on biosimilars? No Yes

Q4b. If yes, was it provided by:
Someone in your Trust Professional Body Pharmaceutical Industry Other

Q4c. When did you have the training? Less than 1 month, 1-3 months ago, 3-6 months ago, more than 6 months

Q4d. How useful was it?
Not at all useful
0 1 2 3 4 5 6 7 8 9 10
Very useful

Q4e. If less than 10, why?
Too brief Not enough detail Too detailed Not relevant to my role Too biased

Other:...........................................

About you

Q5a Role: Nurse Doctor Pharmacist Other (please state) ___________________

Q5b Therapy Area:

Q5c Year of registration as a healthcare professional:

The Cancer Vanguard is a partnership between
Greater Manchester Cancer Vanguard Innovation, RM Partners and UCLH Cancer Collaborative
This resource is a product of the Joint Working Agreement between The Cancer Vanguard and Sandoz

UK/MKT/SDZ/17-0027c(2) June 2017
About the way you learn

Q6a. How do you prefer to learn new information?

Please select 3 in order of preference where 1=first, 2=second and 3=third

<table>
<thead>
<tr>
<th>Learning format</th>
<th>Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentation/Lecture</td>
<td></td>
</tr>
<tr>
<td>Online training</td>
<td></td>
</tr>
<tr>
<td>Ward-based teaching</td>
<td></td>
</tr>
<tr>
<td>Self-directed reading/training</td>
<td></td>
</tr>
<tr>
<td>Attending meetings/congresses</td>
<td></td>
</tr>
<tr>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>Interactive training session</td>
<td></td>
</tr>
<tr>
<td>Other (please describe)</td>
<td></td>
</tr>
</tbody>
</table>

Q6b. On average, how much time do you spend in total on role specific learning each week? Please circle most appropriate.

Less than 15 min  | 30 min  | 1 hr  | 2 hrs  | 3 hrs  | 4 hrs  | 5 hrs  | 6 hrs  | 1 day

Cancer Vanguard

Please note that the following pages are to be used after completion of the training to measure success against the baseline measurements in pages 1, 2 and 3.
Biosimilars Education Impact Assessment Post-Training Questionnaire

After Training

What do you know about biosimilars now?

Q7a. How well do you understand how biosimilar medicines are developed?

I know nothing                                      I have extremely good knowledge
                                                      0  1  2  3  4  5  6  7  8  9  10

Q7b. How well do you understand how biosimilars are licensed in the UK?

I know nothing                                      I have extremely good knowledge
                                                      0  1  2  3  4  5  6  7  8  9  10

Q7c. How well do you understand the concept of extrapolation in regards to biosimilars?

I know nothing                                      I have extremely good knowledge
                                                      0  1  2  3  4  5  6  7  8  9  10

Biosimilars in your practice:

Q8a. How would you expect patients to respond clinically to biosimilars compared to the reference/original medicine?

Very much differently                          Somewhat differently                          Somewhat the same                           Very much the same                           Not Sure
                                                      1  2  3  4  5  6  7  8  9  10

Q8b. How confident would you be in using biosimilars in your patients?

Not at all confident                       Very confident
                                                      0  1  2  3  4  5  6  7  8  9  10

Q8c. How easy do you think it will be to introduce biosimilars into your practice?

Impossible                                Straightforward
                                                      0  1  2  3  4  5  6  7  8  9  10
Talking about biosimilars:

How confident do you feel now at explaining what a biosimilar is to...

Q9a. Clinical colleagues:

<table>
<thead>
<tr>
<th>Not at all confident</th>
<th>Very confident</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 1 2 3 4 5 6 7 8 9</td>
<td>10</td>
</tr>
</tbody>
</table>

Q9b. Patients:

<table>
<thead>
<tr>
<th>Not at all confident</th>
<th>Very confident</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 1 2 3 4 5 6 7 8 9</td>
<td>10</td>
</tr>
</tbody>
</table>

For your role, please list the three biosimilars topics you would like to learn more about?

1. _________________________________________________
2. _________________________________________________
3. _________________________________________________